OptimizeRx CorporationOPRXNASDAQ
Loading
EBITDA Over TimeExpanding
Percentile Rank100
5Y CAGR+90.9%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

5Y CAGR
+90.9%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
25.3x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$16.39M+284.2%
2024$-8.90M+58.3%
2023$-21.31M-126.3%
2022$-9.42M-504.8%
2021$2.33M+259.6%
2020$646895.00+142.8%
2019$-1.51M-222.1%
2018$1.24M+168.5%
2017$-1.81M-38.5%
2016$-1.30M-